KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Retained Earnings (2016 - 2025)

AbbVie (ABBV) has disclosed Retained Earnings for 14 consecutive years, with -$1.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings rose 40.57% to -$1.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.1 billion, a 40.57% increase, with the full-year FY2025 number at -$1.1 billion, up 40.57% from a year prior.
  • Retained Earnings was -$1.1 billion for Q4 2025 at AbbVie, up from -$1.6 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $5.0 billion in Q3 2022 to a low of -$9.5 billion in Q1 2025.
  • A 5-year average of -$755.4 million and a median of -$1.3 billion in 2025 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: soared 375.14% in 2022, then plummeted 632.05% in 2024.
  • AbbVie's Retained Earnings stood at -$2.9 billion in 2021, then skyrocketed by 265.02% to $4.8 billion in 2022, then tumbled by 120.9% to -$1.0 billion in 2023, then plummeted by 92.5% to -$1.9 billion in 2024, then surged by 40.57% to -$1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Retained Earnings are -$1.1 billion (Q4 2025), -$1.6 billion (Q3 2025), and -$1.5 billion (Q2 2025).